Collaboration and License Agreements (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Summary of Revenue from Collaboration and License Agreements

We have recognized revenue from our collaboration and license agreements as follows (in thousands):

	Six Months Ended June 30,
	2012		2013
Novartis:
Recognition of upfront license fee	$	53,282	$	—
Reimbursement of research and development expense		16,064		—
Novartis total		69,346		—
BMS and Pfizer:
Recognition of research and development services		—		3,094
BMS and Pfizer total		—		3,094
Bayer and Janssen:
Recognition of research and development services		—		2,438
Bayer and Janssen total		—		2,438
Lee’s:
Recognition of research and development services		—		52
Lee’s total		—		52
Daiichi Sankyo:
Recognition of research and development services		—		125
Daiichi Sankyo total		—		125
Total collaboration and license revenue	$	69,346	$	5,709

We have recognized revenue from our collaboration and license agreements as follows (in thousands):

	Year Ended December 31,
	2010		2011		2012
Novartis:
Recognition of upfront license fee	$	7,692	$	7,692	$	53,846
Reimbursement of research and development expense		898		1,879		16,238
Novartis total		8,590		9,571		70,084
Merck:
Recognition of upfront license fee		21,429		21,429		–
Reimbursement of research and development expense		5,249		9,973		–
Merck total		26,678		31,402		–
Biogen Idec:
Recognition of upfront license fee		–		37,056		–
Biogen Idec total		–		37,056		–
BMS and Pfizer:
Recognition of research and development services		–		–		1,958
BMS and Pfizer total		–		–		1,958
Total collaboration and license revenue	$	35,268	$	78,029	$	72,042